Vaccines in America in 2026

In this episode, the panelists discuss how the pediatric immunization schedule changes could potentially influence vaccines' inequities, and how vaccine education continues to play a significant role in immunization uptake and improving health equity.

In this episode, the panel discusses the continued importance of getting all children vaccinated and the potential unintended consequences of fewer individuals being immunized if the current trends continue.

The rate of HBV vaccination of newborns in the US has declined by over 10% in the past 2 years, reversing decades of increasing coverage.

The FDA’s biologics center faces another leadership shake-up as Vinay Prasad, MD, MPH, plans an exit in April, leaving questions over vaccine rules and gene-therapy approvals.

The latest CDC numbers show a 12.76% increase of measles cases from week-to-week. This is a slight decrease in the number of cases from last week where there was a 15.7% increase. The data also shows outbreaks in 3 new states.

Despite the absence of vaccine data to support making changes, the ACIP continues to alter the pediatric schedule that will see less children getting immunized against vaccine-preventable diseases.

In this episode of our roundtable discussion, the panelists talk about the changes to the CDC’s ACIP meetings.

As the US continues to undergo massive policy changes to the childhood vaccine schedule, clinicians and families are left uncertain on recommendations and guidance. Our roundtable looks to provide some insights and answer questions to some of the more pressing topics about this evolving issue.

A new modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CPNP, offers commentary on the evolving measles outbreaks, discusses the vulnerable populations that are more at risk for contracting severe measles, and strategies to increase vaccination.

The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows further outbreak spread across more states.

This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.

The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US.

In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule.

The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.

After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will now review the product. The vaccine's PDUFA decision date is August 5, 2026.

The latest CDC numbers show a nearly 25% increase of measles cases from week-to-week. This marks 2 weeks in a row with a nearly identical increase of cases by percentage, and there are now 5 outbreaks circulating throughout the US.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID) describes the potential consequences, including morbidity and mortality rates, if the federal government removed these vaccines.

New amicus brief from scholars and professional organizations including the American Thoracic Society and American Academy of Allergy, Asthma & Immunology supports AAP lawsuit against HHS changes to pediatric vaccine schedule.

The FDA declined to review Moderna’s mRNA flu vaccine application for its mRNA-1010 product, and based its decision on it choice of comparator in a phase 3 trial, despite the absence of safety or efficacy concerns and prior FDA agreement on the study design. Moderna requested a meeting to understand the path forward with the vaccine.

The latest CDC numbers show a significant increase week-to-week.

Paul Offit, MD, voices concerns over the CDC’s surveillance capabilities, the federal agency’s lack of movement to address vaccine needs during outbreaks, and diminishing herd immunity, making the vulnerable at risk for contracting disease.

The Centers for Disease Control and Prevention (CDC) provided its latest figures today on the confirmed number of cases in the US.

The American Academy of Pediatrics (AAP) has published its 2026 immunization schedule, reaffirming routine vaccination to protect children and adolescents against 18 preventable diseases.

Infectious disease pediatrician Sharon Nachman, MD, discusses the vaccine data the federal agency disclosed in the recent letter they sent to the manufacturers.

The workgroup is examining the vaccine’s schedule including the age it is administered, dosage, and the safety and efficacy of the vaccines.

Kirk Milhoan, MD, PhD, said vaccine choice is the most important element to the public even with the possibility of people contracting this disease or others when given the right to opt out of vaccination.

New federal guidance recommends childhood vaccines for 11 diseases, downsizing immunization protection from the previous list of 18 diseases.